Cargando…

Safety of Biologic Therapies in Patients with Moderate-to-Severe Plaque Psoriasis and Concomitant Viral Hepatitis: A Monocentric Retrospective Study

INTRODUCTION: There are no strong data regarding the treatment with biologics (especially for the most recent anti-IL-17 and anti-IL-23 drugs) of patients with psoriasis and concomitant viral hepatitis. We assessed the safety of biologic drugs in patients with psoriasis who are seropositive for hepa...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gargiulo, Luigi, Pavia, Giulia, Valenti, Mario, Lleo de Nalda, Ana, Perugini, Chiara, Costanzo, Antonio, Narcisi, Alessandra
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2022
Materias:	Brief Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9110615/ https://www.ncbi.nlm.nih.gov/pubmed/35460018 http://dx.doi.org/10.1007/s13555-022-00726-w

Ejemplares similares

Real-Life Effectiveness and Safety of Risankizumab in 131 Patients Affected by Moderate-to-Severe Plaque Psoriasis: A 52-Week Retrospective Study
por: Gargiulo, Luigi, et al.
Publicado: (2022)

Risankizumab for the Treatment of Palmoplantar Pustular Psoriasis: a Report of Two Cases
por: Gargiulo, Luigi, et al.
Publicado: (2023)

Sub‐erythrodermic psoriasis successfully treated with bimekizumab: A case report
por: Valenti, Mario, et al.
Publicado: (2022)

Real-life Effectiveness and Safety of Risankizumab in Moderate-to-severe Plaque Psoriasis: A 40-week Multicentric Retrospective Study
por: BORRONI, Riccardo G., et al.
Publicado: (2021)

What Can IBD Specialists Learn from IL-23 Trials in Dermatology?
por: Valenti, Mario, et al.
Publicado: (2022)

Concomitant Pyoderma Gangrenosum-like and Amicrobial Pustulosis of the Folds: a Case Report
por: Facheris, Paola, et al.
Publicado: (2020)

Real-Life Effectiveness and Safety of Upadacitinib in Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis: A Single-Center 16-Week Study
por: Gargiulo, Luigi, et al.
Publicado: (2023)

Anti-interleukin-17 and anti-interleukin-23 biologic drugs for genital psoriasis: a single-center retrospective comparative study
por: Cortese, Andrea, et al.
Publicado: (2023)

Real‐life effectiveness of tildrakizumab in chronic plaque psoriasis: A 52‐week multicentre retrospective study—IL PSO (Italian landscape psoriasis)
por: Narcisi, Alessandra, et al.
Publicado: (2022)

Real-Life Safety and Effectiveness of Dupilumab in Patients with Concomitant Malignancies: a Case Series
por: Gargiulo, Luigi, et al.
Publicado: (2023)

Biologics for the Treatment of Severe Acrodermatitis Continua of Hallopeau: Report of Two Cases Successfully Treated with Ixekizumab and Ustekinumab
por: Gargiulo, Luigi, et al.
Publicado: (2023)

Moderate and severe plaque psoriasis: cost-of-illness study in Italy
por: Colombo, GL, et al.
Publicado: (2008)

Brodalumab for the treatment of plaque psoriasis in a real-life setting: a 3 years multicenter retrospective study—IL PSO (Italian landscape psoriasis)
por: Gargiulo, Luigi, et al.
Publicado: (2023)

Real-World Effectiveness of 9–12 Months of Guselkumab Therapy among Patients with Moderate-to-Severe Plaque Psoriasis in the CorEvitas Psoriasis Registry
por: Armstrong, April W., et al.
Publicado: (2022)

Long-term safety of etanercept in psoriasis: Retrospective study focused on infections
por: Orsini, Diego, et al.
Publicado: (2016)

Stigma Experienced by the Caregivers of Patients with Chronic Plaque Psoriasis
por: Grover, Sandeep, et al.
Publicado: (2021)

Number needed to treat for interleukin inhibitors approved for the treatment of moderate-to-severe plaque psoriasis in Italy
por: Ravasio, Roberto, et al.
Publicado: (2021)

Sonographic Evaluation of Subclinical Enthesopathy in Patients of Chronic Plaque Psoriasis
por: Vyas, Kapil, et al.
Publicado: (2020)

Apremilast in the therapy of moderate-to-severe chronic plaque psoriasis
por: Gisondi, Paolo, et al.
Publicado: (2016)

Risankizumab: A Review in Moderate to Severe Plaque Psoriasis
por: Blair, Hannah A.
Publicado: (2020)

Secukinumab Response in Korean Patients with Moderate to Severe Plaque-Type Psoriasis Irrespective of Previous Biologic Use: 1-Year Experience at a Single Center
por: Kwon, Soo Hyun, et al.
Publicado: (2020)

Effectiveness and safety of bimekizumab for the treatment of plaque psoriasis: a real-life multicenter study—IL PSO (Italian landscape psoriasis)
por: Gargiulo, Luigi, et al.
Publicado: (2023)

A real-world economic analysis of biologic therapies for moderate-to-severe plaque psoriasis in Italy: results of the CANOVA observational longitudinal study
por: Zagni, Emanuela, et al.
Publicado: (2021)

The experience of pain and redness in patients with moderate to severe plaque psoriasis
por: Martin, Mona L., et al.
Publicado: (2015)

Potential role of ixekizumab in the treatment of moderate-to-severe plaque psoriasis
por: Ren, Vicky, et al.
Publicado: (2013)

Clinical utility of ixekizumab in the treatment of moderate-to-severe plaque psoriasis
por: Sekhon, Sahil, et al.
Publicado: (2017)

Correction to: Risankizumab: A Review in Moderate to Severe Plaque Psoriasis
por: Blair, Hannah A.
Publicado: (2020)

Population pharmacokinetics of brodalumab in patients with moderate to severe plaque psoriasis
por: Timmermann, Stine, et al.
Publicado: (2019)

Humanistic and Economic Impact of Moderate to Severe Plaque Psoriasis in Brazil
por: Lopes, Nilcéia, et al.
Publicado: (2019)

Clinical Utility of Guselkumab in the Treatment of Moderate-to-Severe Plaque Psoriasis
por: Light, Jeremy G, et al.
Publicado: (2021)

Secukinumab: A Review in Moderate to Severe Pediatric Plaque Psoriasis
por: Blair, Hannah A.
Publicado: (2021)

Risankizumab for the Treatment of Moderate to Severe Plaque Psoriasis in the Russian Federation
por: Odnopozova, Liudmila, et al.
Publicado: (2022)

Therapeutic Inertia in the Management of Moderate-to-Severe Plaque Psoriasis in Adolescents
por: MELIN, Audrey, et al.
Publicado: (2021)

Clinical Utility of Deucravacitinib for the Management of Moderate to Severe Plaque Psoriasis
por: Jin, Joy Q, et al.
Publicado: (2023)

Cost-Effectiveness of Targeted Pharmacotherapy for Moderate to Severe Plaque Psoriasis
por: Hendrix, Nathaniel, et al.
Publicado: (2018)

Spotlight on ixekizumab for the treatment of moderate-to-severe plaque psoriasis: design, development, and use in therapy
por: Giunta, Alessandro, et al.
Publicado: (2017)

Concomitant Xeroderma pigmentosum and disseminated small plaque psoriasis: first case of an antinomic association
por: Ezzedine, Khaled, et al.
Publicado: (2008)

Treat-to-Target Approach for the Management of Patients with Moderate-to-Severe Plaque Psoriasis: Consensus Recommendations
por: Gisondi, Paolo, et al.
Publicado: (2021)

The Association of Alcohol Use Disorder and Chronic Plaque Psoriasis: Results of a Pilot Study
por: Mahajan, Vikram K., et al.
Publicado: (2020)

Pharmacokinetics of Risankizumab in Asian Healthy Subjects and Patients With Moderate to Severe Plaque Psoriasis, Generalized Pustular Psoriasis, and Erythrodermic Psoriasis
por: Khatri, Amit, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_d1dedcvth6ecjsv6kc0j3499qm